| Alexion Pharmaceuticals is a biopharmaceutical company serving patients and families affected by rare diseases through the discovery, development and commercialization of therapies. Co. has developed and commercialized two complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody positive. In addition, Co. has two enzyme replacement therapies for metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency. |
When researching a stock like Alexion Pharmaceuticals, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from ALXN Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for ALXN stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of those ways is to calculate a Simpe Moving Average ("SMA") by looking back a certain number of days. One of the most popular "longer look-backs" is the ALXN 200 day moving average ("ALXN 200 DMA"), while one of the most popular "shorter look-backs" is the ALXN 50 day moving average ("ALXN 50 DMA"). A chart showing both of these popular moving averages is shown on this page for Alexion Pharmaceuticals. Comparing two moving averages against each other can be a useful visualization tool: by calculating the difference between the ALXN 200 DMA and the ALXN 50 DMA, we get a moving average convergence divergence indicator ("ALXN MACD"). The ALXN MACD chart, in conjunction with the chart of the moving averages, basically helps in visualizing how the moving averages are showing convergence (moving closer together), or divergence (moving farther apart).